Endokrina terapija hormonski ovisnog karcinoma dojke

Beus, Maja; Rajić, Zrinka

prikaz prve stranice dokumenta Endokrina terapija hormonski ovisnog karcinoma dojke

Download
PDF 859.14 KB

Professional paper - Review paper

Endokrina terapija hormonski ovisnog karcinoma dojke

Farmaceutski glasnik, 75 (2019), 6; 445-464. urn:nbn:hr:163:074142

Beus, Maja; Rajić, Zrinka

Cite this document

APA 6th Edition

Beus, M. & Rajić, Z. (2019). Endokrina terapija hormonski ovisnog karcinoma dojke. Farmaceutski glasnik, 75. (6), 445-464. Retrieved from https://urn.nsk.hr/urn:nbn:hr:163:074142

MLA 8th Edition

Beus, Maja and Zrinka Rajić. "Endokrina terapija hormonski ovisnog karcinoma dojke." Farmaceutski glasnik, vol. 75, no. 6, 2019, pp. 445-464. https://urn.nsk.hr/urn:nbn:hr:163:074142

Chicago 17th Edition

Beus, Maja and Zrinka Rajić. "Endokrina terapija hormonski ovisnog karcinoma dojke." Farmaceutski glasnik 75, no. 6 (2019): 445-464. https://urn.nsk.hr/urn:nbn:hr:163:074142

Harvard

Beus, M. and Rajić, Z. (2019) 'Endokrina terapija hormonski ovisnog karcinoma dojke', Farmaceutski glasnik, 75(6), pp. 445-464. Available at: https://urn.nsk.hr/urn:nbn:hr:163:074142 (Accessed 25 April 2024)

Vancouver

Beus M, Rajić Z. Endokrina terapija hormonski ovisnog karcinoma dojke. Farmaceutski glasnik [Internet]. 2019 [cited 2024 April 25];75(6):445-464. Available at: https://urn.nsk.hr/urn:nbn:hr:163:074142

IEEE

M. Beus and Z. Rajić, "Endokrina terapija hormonski ovisnog karcinoma dojke", Farmaceutski glasnik, vol. 75, no. 6, pp. 445-464, 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:163:074142. [Accessed: 25 April 2024]

Cite this item: https://urn.nsk.hr/urn:nbn:hr:163:074142

Please login to the repository to save this object to your list.

Metadata

Title (croatian)	Endokrina terapija hormonski ovisnog karcinoma dojke
Author	Maja Beus
Author	Zrinka Rajić
Author's institution	University of Zagreb Faculty of Pharmacy and Biochemistry (Department of medicinal chemistry)
Scientific / art field, discipline and subdiscipline	BIOMEDICINE AND HEALTHCARE Pharmacy Pharmacy
Abstract (english)	Estrogens are the key female hormones that induce the development of reproductive tissues and secondary sex characteristics. The effects of estrogens are mediated by binding to the estrogen receptors present in the cell cytosole which triggers the translocation of the receptor to the nucleus and transcription of DNA. Other beneficial effects include osteoclast inhibition, prevention of colon cancer, more favourable lipoprotein status, as well as protective cardiovascular effects. However, estrogens also promote the growth of breast cancer that expresses estrogen receptors. The therapeutic goal is the elimination of the estrogen effect on its receptors in the breast cancer tissue, which can be achieved through interference with estrogen biosynthesis or blockade of the estrogen binding to estrogen receptors. Drugs that interfere with estrogen biosynthesis are aromatase inhibitors, agonists and antagonists of gonadotropin-releasing hormone, and adrogens, whereas selective modulators of estrogen receptors and estrogen antagonists block the binding of estrogen. Inhibitors of cyclin-dependent kinases are also a valuable therapeutic option for estrogen-dependent breast cancer.
Keywords (croatian)
Language	croatian
Publication type	Professional paper - Review paper
Publication status	Published
Peer review	Peer review - domestic
Publication version	Published version
Journal title	Farmaceutski glasnik
Numbering	vol. 75, no. 6, pp. 445-464
p-ISSN	0014-8202
URN:NBN	urn:nbn:hr:163:074142
Publication	2019
Type of resource	Text
Access conditions	Open access
Terms of use
Created on	2020-07-07 13:04:41